Kyprolis Study in Newly Diagnosed Disease Doesn't Meet Primary Endpoint—PFS

Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data

The phase I/II LINKER-MM1 trial of linvoseltamab in R/R MM produced positive pivotal data in patients with relapsed/refractory multiple myeloma.

April 12, 2024

Vol.50 No.15

Drugs & Targets

FDA approves Abecma for earlier lines of treatment for MM

FDA approved Abecma (idecabtagene vicleucel; ide-cel) for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody, based on results from the KarMMa-3 trial (The Cancer Letter, March 22, 2024).

April 05, 2024

Vol.50 No.14

Clinical Roundup

RCSI preclinical research identifies promising drug combination for MM treatment

Royal College of Surgeons in Ireland preclinical research found that venetoclax, a medication currently approved for leukemia, may have benefits for patients with multiple myeloma when used in combination with another drug—a demethylase inhibitor called 5-azacytidine. This discovery offers a new avenue of treatment options for the currently incurable disease.

March 29, 2024

Vol.50 No.13

Drugs & Targets

FDA grants orphan drug designation to Heidelberg Pharma agent for MM

FDA granted HDP-101 orphan drug designation in multiple myeloma.

March 29, 2024

Vol.50 No.13

Conversation with The Cancer Letter

Kathy Giusti’s “Fatal to Fearless” memoir tells the story of prevailing over multiple myeloma
Book offers 12 steps to beating cancer in a broken medical system

Sometimes in oncology, you get “beat-the-reaper” stories.

Phase III Blenrep trial in multiple myeloma produces positive topline results

An interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or refractory multiple myeloma, showed that the trial met its primary endpoint of progression-free survival at a prespecified interim analysis and was unblinded early based on the recommendation by an Independent Data Monitoring Committee.

March 08, 2024

Vol.50 No.10

Kyprolis Study in Newly Diagnosed Disease Doesn’t Meet Primary Endpoint—PFS

YOU MAY BE INTERESTED IN

Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data

FDA approves Abecma for earlier lines of treatment for MM

RCSI preclinical research identifies promising drug combination for MM treatment

FDA grants orphan drug designation to Heidelberg Pharma agent for MM

Kathy Giusti’s “Fatal to Fearless” memoir tells the story of prevailing over multiple myeloma
Book offers 12 steps to beating cancer in a broken medical system

Phase III Blenrep trial in multiple myeloma produces positive topline results

Renew today!

Subscriber content

Login

Kyprolis Study in Newly Diagnosed Disease Doesn’t Meet Primary Endpoint—PFS

YOU MAY BE INTERESTED IN

Phase I/II trial of linvoseltamab in R/R MM produces positive pivotal data

FDA approves Abecma for earlier lines of treatment for MM

RCSI preclinical research identifies promising drug combination for MM treatment

FDA grants orphan drug designation to Heidelberg Pharma agent for MM

Kathy Giusti’s “Fatal to Fearless” memoir tells the story of prevailing over multiple myelomaBook offers 12 steps to beating cancer in a broken medical system

Phase III Blenrep trial in multiple myeloma produces positive topline results

Login

Kathy Giusti’s “Fatal to Fearless” memoir tells the story of prevailing over multiple myeloma
Book offers 12 steps to beating cancer in a broken medical system